https://www.aigom.it/wp-content/uploads/2024/05/loc27.5.png676950Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-20 07:48:582024-05-20 07:49:5827 MAGGIO 2024-PADUA MASTERCLASS IN NEURO-ONCOLOGY
https://www.aigom.it/wp-content/uploads/2024/05/art.21.5.png1063935Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-17 09:32:042024-05-17 09:32:04FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2024/05/artcolo14.5.png1093958Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-13 08:07:202024-05-13 08:07:20ELACESTRANT (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL.
https://www.aigom.it/wp-content/uploads/2024/05/loc-10.11.5.png379270Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-02 09:59:132024-05-14 07:33:13VENERDI 10-SABATO 11 MAGGIO 2024 NEGRAR DI VALPOLICELLA (VR) SCUOLA DI METODOLOGIA CLINICA
https://www.aigom.it/wp-content/uploads/2024/05/loc9maggio.png417313Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-05-02 09:40:292024-05-14 07:28:24GIOVEDI 9 MAGGIO 2024 NEGRAR DI VALPOLICELLA (VR) SCUOLA DI METODOLOGIA DELLA RICERCA CLINICA
https://www.aigom.it/wp-content/uploads/2024/04/chicagolocandina.png719400Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-26 08:03:542024-06-07 08:59:23AIGOM-LE NOVITA’ DA CHICAGO 2024: L’EVOLUZIONE DELLE CONOSCENZE IN ONCOLOGIA…
https://www.aigom.it/wp-content/uploads/2024/04/ib3-3.png376294Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-22 08:21:522024-05-09 14:38:50OSSERVATORIO CIVILE E CITTADINANZA ATTIVA- NGS E MTB: LO STATO DELL’ARTE REGIONALE-INSTANT BOOK
https://www.aigom.it/wp-content/uploads/2024/04/ANONCOL.png12441097Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2024-04-18 12:22:432024-04-23 08:17:23EVENT-FREE SURVIVAL BY RESIDUAL CANCER BURDEN WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC): EXPLORATORY ANALYSIS FROM KEYNOTE-522
